French drugmaker Sanofi and Britain’s GlaxoSmithKline will supply 200 million doses of their COVID-19 candidate vaccine to a global inoculation scheme backed by the World Health Organization. COVAX, which aims to deliver 2 billion vaccine doses around the world by the end of 2021, has already sealed agreements this year with AstraZeneca and Novavax. Sanofi and GSK signed a $2.1 billion deal with Washington during the summer to supply it with more than 100 million doses of the same vaccine, which they hope to present for regulatory approval next year.
